<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>InSpiro &#187; David Marquez</title>
	<atom:link href="http://inspiro-bg.com/author/david-marquez/feed/" rel="self" type="application/rss+xml" />
	<link>https://inspiro-bg.com</link>
	<description>Списание за респираторна медицина и вдъхновение</description>
	<lastBuildDate>Fri, 23 Oct 2026 08:08:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.2.1</generator>
		<item>
		<title>Efficacy and Safety of Viusid and Asbrip in Hospitalized Patients with Mild and Moderate COVID-19: A Randomized Controlled Trial</title>
		<link>https://inspiro-bg.com/efficacy-and-safety-of-viusid-and-asbrip-in-hospitalized-patients-with-mild-and-moderate-covid-19-a-randomized-controlled-trial/</link>
		<comments>https://inspiro-bg.com/efficacy-and-safety-of-viusid-and-asbrip-in-hospitalized-patients-with-mild-and-moderate-covid-19-a-randomized-controlled-trial/#comments</comments>
		<pubDate>Tue, 02 May 2023 08:02:49 +0000</pubDate>
		<dc:creator>David Marquez</dc:creator>
				<category><![CDATA[2022]]></category>
		<category><![CDATA[Акцент на началната страница]]></category>
		<category><![CDATA[Архив]]></category>
		<category><![CDATA[Брой № 5 (68) / декември 2022]]></category>
		<category><![CDATA[Рубрики]]></category>
		<category><![CDATA[Самородни]]></category>

		<guid isPermaLink="false">http://inspiro-bg.com/?p=17026</guid>
		<description><![CDATA[Резюме &#160; ИЗВАДКА С ПРЕВОД НА БЪЛГАРСКИ Статията е налична на: https://www.scirp.org/journal/paperinformation.aspx?paperid=109173 &#160; Цели: Целта на това проучване е да се тестват Viusid и Asbrip като адюванти към стандартното лечение на пациенти с болест COVID-19, което би могло да благоприятства възстановяването на пациентите и да намали дните на хоспитализация. Дизайн: Това е рандомизирано, отворено, контролирано]]></description>
		<wfw:commentRss>https://inspiro-bg.com/efficacy-and-safety-of-viusid-and-asbrip-in-hospitalized-patients-with-mild-and-moderate-covid-19-a-randomized-controlled-trial/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
